iBio will host a corporate update call on March 17 at 4 p.m. ET featuring CEO Martin Brenner and Dr. Cory Schwartz to discuss its strategic expansion into pulmonary hypertension associated with HFpEF. The webcast and replay will be accessible via the company’s investor relations website.

iBio is engineering a selective bispecific antibody designed to block Activin A, GDF8 (myostatin) and GDF11 aiming to reduce cardiac fibrosis, reverse pulmonary vascular remodeling and improve functional capacity while avoiding broader TGF-β safety issues. This multi-target approach seeks to fill a gap in current PH-HFpEF therapies by addressing core disease drivers simultaneously.

iBio expects to nominate the optimized bispecific antibody development candidate—validated for potency, selectivity, manufacturability and in vivo efficacy—by the third quarter of 2026. Following this selection, the program will enter IND-enabling activities as the company advances its PH-HFpEF pipeline.